Effects of trimebutine maleate on gastric motility in patients with gastric ulcer. 1998

T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
Third Department of Internal Medicine, Nagoya City University Medical School, Nagoya, Japan.

The effects of trimebutine maleate (TM), a prokinetic drug, on gastrointestinal motility in patients with gastric ulcer were investigated. Twenty patients with active gastric ulcers were allocated to two groups; 10 patients received a proton pump inhibitor alone (PPI group), given orally, and 10 patients received oral TM in combination with a PPI (PPI + TM group), each for a period of 8 weeks. Electrogastrography (EGG) and gastric emptying were measured before and after the treatment period. During the active ulcer stage, tachygastria (more than 0.06 Hz) or bradygastria (less than 0.04 Hz) in the EGG frequency were observed in 9 patients either before or after meals. During the healed ulcer stage, tachygastria or bradygastria was observed in 4 of 10 patients in the PPI group, while in the PPI + TM group, 1 patient had tachygastria and none had bradygastria. Postprandial dip (PD) was observed in 3 of the 20 patients during the active stage, while after treatment, PD was observed in 3 patients in the PPI group and in 6 patients in the PPI + TM group, respectively. Gastric emptying in the PPI group did not show any change between before and after treatment, while that in the PPI + TM group improved significantly after treatment. These results suggest that TM may have an ameliorative effect on abnormal gastric motility in patients with gastric ulcer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005746 Gastric Emptying The evacuation of food from the stomach into the duodenum. Emptying, Gastric,Emptyings, Gastric,Gastric Emptyings
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal

Related Publications

T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
December 1998, Journal of gastroenterology,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
August 1999, Annals of nuclear medicine,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
October 1982, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
October 1984, Nihon Heikatsukin Gakkai zasshi,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
March 1982, Nihon Heikatsukin Gakkai zasshi,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
February 1989, Presse medicale (Paris, France : 1983),
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
June 2011, Archives of pharmacal research,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
June 1949, Surgo; Glasgow University medical journal,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
July 1998, Alimentary pharmacology & therapeutics,
T Kamiya, and T Nagao, and T Andou, and N Misu, and Y Kobayashi, and M Hirako, and M Hara, and T Fujinami
December 1980, La Clinica terapeutica,
Copied contents to your clipboard!